Mektovi

What Mektovi Means in Everyday Medical Language

Mektovi is the brand name for the drug binimetinib, a type of targeted cancer medicine called a kinase inhibitor. It works by blocking proteins inside cancer cells called MEK1 and MEK2. These proteins are part of a chain of signals that tell cells to grow and divide. In some cancers, especially melanoma with a change in the BRAF gene, this signaling is overactive, causing cancer cells to grow uncontrollably. By blocking MEK1 and MEK2, Mektovi helps slow or stop the growth of these cancer cells.

Why Mektovi Can Matter in Cancer Care

Mektovi is important because it targets a specific change in cancer cells rather than attacking all rapidly dividing cells like traditional chemotherapy. It is mainly used with another drug called encorafenib to treat melanoma that has spread or cannot be removed by surgery, especially when the cancer has a mutation in the BRAF gene. This mutation causes the cancer to grow faster, and Mektovi helps block the signals that drive this growth. Using Mektovi as part of targeted therapy can improve treatment options for patients with this specific type of melanoma. It is also being studied for other cancers, such as certain lung cancers.

What Patients Might See or Hear About Mektovi

Patients may hear about Mektovi during discussions about treatment options if their tumor has been tested and found to have a BRAF mutation. Doctors often use genetic testing to find this mutation, which helps guide whether Mektovi and encorafenib might be effective. Mektovi is usually given as a pill and is part of a combination treatment plan. Patients might see the name Mektovi or binimetinib on medication lists, treatment plans, or clinical trial information. It is important to understand that Mektovi is not chemotherapy but a targeted therapy that works differently.

What Mektovi Does Not Automatically Mean

Hearing about Mektovi does not mean the cancer is cured or that this drug will work for all types of melanoma or other cancers. Mektovi is only used when the cancer has a specific BRAF mutation, and even then, it may not be effective for everyone. It is not a chemotherapy drug and does not affect all cancer cells the same way. Also, Mektovi is not approved for all cancers, though it is being studied in clinical trials for some others. Patients should not assume Mektovi will be part of every treatment plan or that it works alone without other medicines.

How Doctors Use Mektovi in Treatment Planning

Doctors test tumors for the BRAF mutation to decide if Mektovi is a suitable treatment option. It is most often combined with encorafenib to block different parts of the cancer’s growth signals. This combination is used when melanoma has spread or cannot be removed by surgery. Your healthcare team will monitor your response to treatment and manage any side effects. Mektovi is part of a personalized treatment approach that targets specific changes in cancer cells.

How Mektovi Connects to Related Treatments

Mektovi is often given with encorafenib, another targeted drug that blocks proteins made by the mutated BRAF gene. Together, they work to slow or stop cancer growth more effectively than either drug alone. This combination is approved for certain melanomas and some lung cancers with the BRAF mutation. Understanding these connections can help patients follow their treatment plan and ask informed questions.

Safety and Next Steps

This information is meant to help patients and caregivers understand Mektovi better but does not replace medical advice. Every patient’s situation is unique, and treatment decisions should be made with a healthcare team. If you have questions about Mektovi or your treatment options, talk with your doctor or nurse. Learning about Mektovi can be a helpful step if you or a loved one has melanoma or another cancer with a BRAF mutation. Ask your care team if this drug might be part of your treatment and what to expect during therapy.